3.8000 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||3.7400 x 3200|
|Ask||3.8900 x 900|
|Day's Range||3.7000 - 3.8250|
|52 Week Range||3.0200 - 6.3000|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
While many biopharmaceutical companies have partnerships or collaborations with one or two larger companies, Inovio Pharmaceuticals has product development deals in place with more than a half dozen pharmaceutical and biotech firms and research organizations inside and outside the United States. Inovio is in that position largely because it is developing a technology platform with two parts that can be applied to a variety of medical conditions. The second part is the system for delivering the therapy through the skin or into muscle tissues using brief and low voltage electronic pulses. That standing, said Inovio co-founder and CEO J. Joseph Kim, gives the Plymouth Meeting-based company different aspirations than other development-stage drug developers.
PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inovio's dBiTE results were published in a JCI Insight article entitled, "DNA-encoded bi-specific T cell engagers and antibodies present long-term antitumor activity," by Inovio and its collaborators at The Wistar Institute. JCI Insight is a peer-reviewed journal published by the American Society for Clinical Investigation dedicated to well-executed preclinical and clinical research studies.
In a recent press release, Inovio (INO) said they completed enrollment three months ahead of schedule in the Phase 1/2, 52-patient trial of INO-5401 for newly-diagnosed glioblastoma, asserts Michael Murphy, growth stock expert and editor of New World Investor.
PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders. Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate the World Vaccine Congress' recognition of Inovio's breakthrough immunotherapy VGX-3100 that could offer the first non-surgical treatment to patients who are suffering from HPV-related pre-cancers that often progress to cancer.
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you own shares in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) then it's worth thinking about how it contributes to the volat...
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
PLYMOUTH MEETING, Pennsylvania , April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing ...
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
PLYMOUTH MEETING, Pennsylvania, April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated disease that can cause noncancerous tumor growths leading to life-threatening airway obstructions, and occasionally progresses to cancer. RRP is primarily caused by two strains of HPV, HPV 6 and 11, which also predominantly cause genital warts.
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
PLYMOUTH MEETING, Pennsylvania, April 2, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs™) generated potent anti-tumor activities in a preclinical study. For this study, Inovio, with its collaborators at The Wistar Institute, developed a novel dBiTE targeting the HER2 molecule which was tested in therapeutic models for the treatment of ovarian and breast cancers. Importantly, just a single dose of Inovio's HER2 dBiTE resulted in high levels of corresponding BiTE in mice for four months, far exceeding what is typically displayed with conventional BiTE's short half-life of only a few hours.
PLYMOUTH MEETING, Pa., April 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule. The 52-patient trial is designed to evaluate Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens expressed by GBM and INO-9012, an immune activator encoding IL-12, in combination with cemiplimab-rwlc (also known as Libtayo® or REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals in collaboration with Sanofi. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, "We sincerely thank the patients and their doctors for participating in our innovative combination trial.
PLYMOUTH MEETING, Pa., March 27, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 4:10 p.m. local time. The conference is being held at the Grosvenor House Hotel in London, UK. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
PLYMOUTH MEETING, Pa. , March 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding ...
PLYMOUTH MEETING, Pa., March 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, the study demonstrated that intradermal (skin) administration with Inovio's CELLECTRA® delivery device resulted in 100% of evaluable subjects generating antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses equivalent to or better than the group that received intramuscular delivery.
Shares of Inovio Pharmaceuticals Inc. rose 9% in premarket trade Thursday after the company announced that its investigational Ebola vaccine was able to elicit a strong antibody response in the majority of subjects in a Phase 1 trial. The vaccine, dubbed INO-4201, was given to 70 subjects either through a skin injection or an injection into muscle. Of those subjects, 67 were able to mount a strong antibody response to an Ebola antigen after three doses, while 52 were able to do so after only two doses, the company said. Inovio noted that the 13 subjects who received the vaccine through a skin injection were all able to mount an antigen-specific antibody response after just two doses. The vaccine, which is non-live as opposed to other investigational Ebola vaccines based on viral vectors, has not shown any serious systemic adverse effects like fever, joint pain or low white blood cell count, the company said. Shares of Inovio have fallen 10% in the year to date, while the S&P 500 has gained 12.7%.
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.